Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01227278 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 421
- Enrollment target
NCT01227278 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 421 participants.
The verdict
NCT01227278, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 421 participants
- Enrollment target
Study Summary
To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.
Interventions
- OTHER Placebo
- BIOLOGICAL Benralizumab 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 421 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01227278
The ClinicalTrials.gov registry entry for NCT01227278 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 421 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01227278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01227278 about?
NCT01227278 is a clinical study titled "A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.
What is the current status of trial NCT01227278?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 421 participants. The study started on 2010-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01227278?
The interventions under investigation include: Placebo (OTHER), Benralizumab 100 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT01227278?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.